Turn Therapeutics Inc.
About Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$3.2M
- Total assets
- $12.2M
- Market cap
- $157.3M
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $5.9M
- Operating income
- -$5.9M
- Net income
- -$3.2M
- EPS (basic)
- $-0.12
- EPS (diluted)
- $-0.12
Balance sheet
- Total assets
- $12.2M
- Current assets
- $5.2M
- Total liabilities
- $7.5M
- Current liabilities
- $6.0M
- Shareholders’ equity
- $4.7M
Cash flow
- Operating cash flow
- -$2.6M
- Investing cash flow
- -$153.0K
- Financing cash flow
- $6.9M
- Net cash flow
- $4.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $157.3M
- EPS (diluted)
- $-0.12
- Shares outstanding
- 29.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $3.2M.
- Trading 42% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Turn Therapeutics Inc..
